The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Announces February 2012 Investor Conference Presentations

Tuesday, February 21, 2012

Regeneron Announces February 2012 Investor Conference Presentations16:05 EST Tuesday, February 21, 2012TARRYTOWN, N.Y., Feb. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:Citi 2012 Global Healthcare Conference at 3:00 p.m. Eastern Time on Tuesday, February 28, 2012 RBC Capital Markets' Healthcare Conference at 9:00 a.m. Eastern Time on Wednesday, February 29, 2012The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page.  Archived versions of the presentations will be available for thirty days after the live webcasts.  Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:   Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications                            914-847-5126914.847.7640              manisha.narasimhan@regeneron.com peter.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.